Objective To compare the clinical efficacy of recombinant human endostatin injection (Endo) combined with pemetrexed and cisplatin chemotherapy with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma.Methods 81 patients with advanced lung adenocarcinoma diagnosed by histopathology or cytology were randomly divided into observation group (41 cases) and control group (40 cases) . Both groups were given pemetrexed + cisplatin (PP regimen) chemotherapy, and the observation group was given en-degree treatment on this basis. The short-term clinical efficacy of the two groups was evaluated. The quality of life (KBS) score was used to evaluate the quality of life before and after treatment and the adverse reactions during the treatment. The median progression time was calculated.Results The effective rate of the observation group was 46.15％, which was higher than that of the control group 37.50％, the difference was statistically significant (P ＜0.05) .The median tumor progression time of the observation group was 8.65 months, which was higher than the control group of 5.31 months, the difference was statistically significant (P＜0.05) .There was no significant difference in the quality of life scores and adverse reactions between the two groups (P＞0.05) .Conclusion Endo combined with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma can improve the short-term clinical efficacy, prolong the tumor progression time, improve the quality of life, and does not increase adverse reactions, and has good clinical efficacy and safety.%目的 比较重组人血管内皮生成抑制素注射液 (恩度) 联合培美曲塞及顺铂化疗方案与单用培美曲塞联合顺铂方案治疗晚期肺腺癌的临床疗效.方法 选取81例经病理组织学或细胞学检查确诊的晚期肺腺癌初治患者, 随机分为观察组 (41例) 和对照组 (40例) .两组患者均给予培美曲塞+顺铂 (PP方案) 化疗, 观察组在此基础上给予恩度治疗.评价两组近期临床疗效, 采用生活质量卡氏 (KBS) 评分评价患者治疗前后生存质量及治疗期间不良反应, 计算中位进展时间.结果 观察组近期有效率为46.15％, 高于对照组的37.50％, 差异有统计学意义 (P＜0.05) ;观察组中位肿瘤进展时间为8.65个月, 高于对照组的5.31个月, 差异有统计学意义 (P＜0.05) ;两组生活质量评分及不良反应发生率比较, 差异无统计学意义 (P＞0.05) .结论 恩度联合培美曲塞+顺铂治疗晚期肺腺癌可提高近期临床疗效, 延长肿瘤进展时间, 改善生活质量, 且不增加不良反应, 具有较好的临床疗效及安全性.
展开▼
